---
layout: talk_reveal3
title: Perspectives on SARS-CoV-2 evolution
venue: SXSW 2021
author: Trevor Bedford
widescreen: true
---

<!-- 5-7 min talk time -->

<!--
Outline:
- Tracking evolution via Nextstrain
- Variants of concern, emergence and spread
- Forecasts for antigenic evolution
- Long-term prospects
- Forecasting SARS-CoV-2 evolution
- Metagenomics for early pandemic warning
-->

<section data-background-iframe="/talks/viz/gradient/">
	<h2 class="title">{{ page.title }}</h2>
	<br>&nbsp;<br>
	<p class="title">
	Trevor Bedford (@trvrb)
	<br>
	Associate Professor, Fred Hutchinson Cancer Research Center
	<br>
	{{ page.date | date: "%-d %b %Y" }}
	<br>
	{{ page.venue }}
	<br>&nbsp;<br>
	Slides at: bedford.io/talks
</section>

<section>
	<h3>Over 800k SARS-CoV-2 genomes shared to GISAID and evolution tracked in real-time at nextstrain.org</h3>
	<img class="stretch" data-src="/images/talks/ncov_tree_map_2021_03_07_global.png">
	<div class="citation">
		<a href="https://nextstrain.org">nextstrain.org</a>
	</div>
</section>

<section>
	<h3>Spike protein is critical for cell invasion by the virus and is the primary target for human immune response</h3>
	<img class="stretch" data-src="/images/talks/sars_cov_2_spike_structure.png">
	<div class="citation">
		<a href="https://science.sciencemag.org/content/367/6483/1260">Wrapp et al. 2020. Science.</a>
	</div>
</section>

<section>
	<h3>Spike mutations 484K and 501Y appearing repeatedly</h3>
	<img class="stretch" data-src="/images/talks/ncov_variants_484K_501Y_2021_03_07.png">
	<div class="citation">
		<a href="https://nextstrain.org/ncov/global?c=gt-S_484,501">nextstrain.org</a>
	</div>
</section>

<section>
	<h3>Emergence of 501Y.V1 (B.1.1.7) in the UK</h3>
	<img class="stretch" data-src="/images/talks/ncov_variants_501Y.V1_clock_2021_02_10.png">
	<div class="citation">
		<a href="https://nextstrain.org/groups/neherlab/ncov/united-kingdom?c=clade_membership&f_country=United%20Kingdom&l=clock&r=division">nextstrain.org</a>
	</div>
</section>

<!-- <section>
	<h3>Emergence of 501Y.V2 (B.1.351) in the South Africa</h3>
	<img class="stretch" data-src="/images/talks/ncov_variants_501Y.V2_clock_2021_02_10.png">
	<div class="citation">
		<a href="https://nextstrain.org/ncov/africa?f_country=South%20Africa&l=clock&r=division">nextstrain.org</a>
	</div>
</section>

<section>
	<h3>Emergence of 501Y.V3 (P.1) in the Brazil</h3>
	<img class="stretch" data-src="/images/talks/ncov_variants_501Y.V3_clock_2021_02_10.png">
	<div class="citation">
		<a href="https://nextstrain.org/ncov/south-america?f_country=Brazil&l=clock&r=division">nextstrain.org</a>
	</div>
</section> -->

<section>
	<h3>Up to December, my expectation was evolution as seen in seasonal coronaviruses with flu B-like rates of evolution</h3>
	<img class="stretch" data-src="/images/talks/seasonal_cov_adaptation_rate_comparison_elife.jpg">
	<div class="citation">
		<a href="/papers/kistler-hcov-adaptive-evolution/">Kistler and Bedford. 2021. eLife.</a>
	</div>
</section>

<section>
	<h3>Rapid spike S1 amino acid evolution in SARS-CoV-2</h3>
	<img class="stretch" data-src="/images/talks/ncov_mutation_rate_spike_clock_2021_02_05.png">
</section>

<!-- <section>
	<h3>SARS-COV-2 spike S1 evolution similar to evolution of flu H3N2</h3>
	<img class="stretch" data-src="/images/talks/flu_mutation_rate_ha1_clock_across_subtypes.png">
</section> -->

<section class="left-align">
	<h3>It's possible evolution of SARS-CoV-2 will slow down, but I wouldn't count on it</h3>
	<p>
	<ol>
		<li>Flu H3N2 rates of evolution suggest vaccine updates every 1-2 years</li>
		<li>Flu H3N2 infects 5-10% of the US every year</li>
		<li>Similar levels of SARS-CoV-2 circulation possible (though mRNA vaccines are amazing)</li>
	</ol>
	</p>
</section>

<section class="left-align">
	<h3>Importance of predictive modeling of SARS-CoV-2 evolution</h3>
	<p>
	<ol>
		<li>Forecasting evolution in seasonal influenza has seen some success</li>
		<li>Huge amount of data available for SARS-CoV-2</li>
	</ol>
	</p>
</section>

<section class="left-align">
	<h3>Given flu-like evolution, my general speculation looks like</h3>
	<p>
	<ol>
		<li>Infections of previously vaccinated / infected individuals are likely to be milder</li>
		<li>A winter "COVID" season with significant SARS-CoV-2 circulation but lower levels COVID-19 disease</li>
		<li>Voluntary yearly COVID vaccine for people who are interested in increased protection from circulating viruses</li>
		<li>Depending on level of circulation/disease continued push for case finding / contact tracing, but I'd hope to avoid societal restrictions</li>
	</ol>
	</p>
</section>

<section class="left-align">
	<h3>Continued improvements to sequencing throughput of common viral infections can provide early warning system for emerging pandemic threats</h3>
</section>

<section>
	<h3>Acknowledgements</h3>

	<p class="even-smaller">
		<b>SARS-CoV-2 genomic epi</b>: Data producers from all over the world, GISAID and the Nextstrain team
	</p>

	<p class="tiny"><b>Bedford Lab</b>:
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/allison-black.jpg"> Alli Black,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/john-huddleston.jpg"> John Huddleston,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/james-hadfield.jpg"> James Hadfield,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/katie-kistler.jpg"> Katie Kistler,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/louise-moncla.jpg"> Louise Moncla,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/maya-lewinsohn.jpg"> Maya Lewinsohn,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/thomas-sibley.jpg"> Thomas Sibley,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/jover-lee.jpg"> Jover Lee,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/kairsten-fay.jpg"> Kairsten Fay,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/misja-ilcisin.jpg"> Misja Ilcisin,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/cassia-wagner.jpg"> Cassia Wagner,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/miguel-paredes.jpg"> Miguel Paredes,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/nicola-mueller.jpg"> Nicola MÃ¼ller,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/marlin-figgins.jpg"> Marlin Figgins,</span>
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/eli-harkins.jpg"> Eli Harkins</span>
	</p>

	<div class="pull-right" style="vertical-align: bottom; display: table-cell;">
		<img width="11%" data-src="/images/talks/logo_fred_hutch_vertical.png">
		&nbsp; &nbsp;
		<img width="8%" data-src="/images/talks/logo_pew.png">
		&nbsp; &nbsp;
		<img width="14%" data-src="/images/talks/logo_bmgf.png">
		&nbsp; &nbsp;
		<img width="12%" data-src="/images/talks/logo_gates_ventures.png">
		&nbsp; &nbsp;
		<img width="11%" data-src="/images/talks/logo_wellcome_trust.jpg">
		&nbsp; &nbsp;
		<img width="7%" data-src="/images/talks/logo_nih.jpg">
		&nbsp; &nbsp;
		<img width="12%" data-src="/images/talks/logo_osp.jpg">
	</div>
</section>
